-
Burning Rock Reports Q4 Revenue Growth Amid Improved Profitability
•
Guangzhou-based medical device company Burning Rock (NASDAQ: BNR) has released its Q4 2024 financial results. The company reported Q4 revenues of RMB 126 million (USD 17.3 million), representing a 4.1% year-on-year (YOY) increase. For the full year, revenues reached RMB 515.8 million (USD 71 million), a 4.0% YOY decrease. Despite…
-
Burning Rock and MGI Tech Partner to Advance Oncology Precision Medicine
•
China-based medtech firm Burning Rock Ltd (NASDAQ: BNR) has entered into a strategic partnership with fellow domestic company MGI Tech Co., Ltd (SHA: 688114), a gene sequencing specialist. The collaboration aims to promote the clinical application and global business development of oncology precision medicine, with a focus on regulatory filing…
-
Burning Rock Ltd Reports Q3 2024 Financials with Revenue Growth and R&D Reduction
•
China-based medtech firm Burning Rock Ltd (NASDAQ: BNR) has released its financial results for the third quarter of 2024. The company reported Q3 revenues of RMB 128.6 million (USD 18.3 million), marking a year-on-year (YOY) increase of 0.8%. Research and development (R&D) expenses saw a significant decline of 41.3% YOY,…
-
Sunvozertinib’s Companion Diagnostic Gets NMPA Nod, Fortifying Targeted Therapy Arsenal for NSCLC in China
•
Dizal Pharmaceutical Co., Ltd (SHA: 688192) and Burning Rock Ltd (NASDAQ: BNR, FRA: 6BU0) have announced a significant regulatory milestone in China’s precision medicine space. Their jointly developed companion diagnostic (CDx) for epidermal growth factor receptor (EGFR) exon 20 insertion mutations (exon20ins), designed to pair with the targeted therapy sunvozertinib,…
-
Burning Rock Expands Companion Diagnostics Partnership with Bayer for Precision Oncology in China
•
Burning Rock Ltd (NASDAQ: BNR), a China-based medical technology company, has announced another partnership in the field of tumor companion diagnostics (CDx), this time with the German multinational corporation, Bayer. Previously Burning Rock had collaborated with Germany-based Merck KGaA in late 2021 for the development of CDx to support Merck’s…
-
Burning Rock’s CanCatch MRD Product Shows Superiority in Postoperative NSCLC Monitoring
•
China-based medtech firm Burning Rock Ltd (NASDAQ: BNR) has revealed positive findings from a five-year clinical trial of its liquid assay-based personalized minimal residual disease (MRD) product, CanCatch (PROPHET panel; Patient-specific pROgnostic and Potential tHErapeutic marker Tracking). The results, published in Cancer Cell under the title “Individualized tumor-informed circulating tumor…
-
Burning Rock Partners with AstraZeneca to Develop Companion Diagnostics for Cancer Therapies
•
Guangzhou-based medical device giant Burning Rock (NASDAQ: BNR) has announced a strategic partnership with AstraZeneca (AZ, NASDAQ: AZN). The collaboration will utilize Burning Rock’s world-leading testing technology and high-quality, standardized testing capacities to develop and commercialize companion diagnostics (CDx) products for AstraZeneca’s breast cancer and prostate cancer therapies. Financial details…
-
Burning Rock Reports Q4 2022 Revenue Dip but 10.9% Full-Year Growth
•
Guangzhou-based medical device company Burning Rock (NASDAQ: BNR) has released its financial results for the fourth quarter of 2022. The company reported Q4 revenues of CNY 142.2 million (USD 20.6 million), marking a 3.5% decrease year-on-year (YOY). However, for the full 12 months, revenues showed a positive trend, increasing by…
-
Burning Rock Upgrades 2022 Revenue Growth Forecast to 10% YOY
•
Guangzhou-based medical device giant Burning Rock Ltd (NASDAQ: BNR) has issued a notice upgrading its guidance on expected revenue growth for 2022. The company now projects a 10% year-on-year (YOY) increase, up from the 5% announced in November last year. This upward revision is driven by a better-than-forecast performance in…
-
Eli Lilly Partners with AmoyDx and Burning Rock for Retevmo Companion Diagnostics
•
The 5th China International Import Expo (CIIE) saw US-based Eli Lilly (NYSE: LLY) announce a partnership with China-based Amoy Diagnostics Co., Ltd (AmoyDx) and Burning Rock Biotech Ltd (NASDAQ: BNR). The collaboration aims to enhance the development of companion diagnostics (CDx) for Retevmo (selpercatinib), the world’s first highly-selective RET kinase…
-
Burning Rock Biotech Launches PREVENT Study for Early Cancer Detection
•
Chengdu-based medical device firm Burning Rock Biotech Ltd (NASDAQ: BNR) announced the launch of a ground-breaking interventional validation study focused on the application of its early cancer test, OverC, in detecting various cancer types in asymptomatic patients. The PREVENT (Prospective multi-canceR Early-detection and interVENTional) study will enroll 12,500 individuals to…
